Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
World Vitiligo Map
Your guide to the vitiligo community worldwide. Use the selector to filter by patient support groups, specialists, research centers, clinical trial locations, or World Vitiligo Day events.
Directory Information & Disclaimer
This free public directory gathers information from public sources to help connect our global community. Medical professionals and organizations listed are independent and not affiliated with or endorsed by the Vitiligo Research Foundation (VRF), and no fees are accepted for listings.
Because clinics, support groups, and specialists move or update their services over time, some information may occasionally become outdated. As a result, VRF cannot guarantee the complete accuracy or usefulness of listed third-party resources.
Help Us Keep the Map Accurate
Do you need to add a listing, update outdated details, or request a removal? Please reach out to us using the feedback form on our Contact Us page.
Search Map
70 records found for “NCT07431177” · show all
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Hamburg, 20354, Germany
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Hanover, 30625, Germany
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Lübeck, 23538, Germany
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Tübingen, 72076, Germany
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Ahmedabad, Gujarat, 380016, India
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Bangalore, Karnataka, 560074, India
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Mysore, Karnataka, 570001, India
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Cona, FE, 44124, Italy
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Milan, MI, 20122, Italy
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Rozzano, MI, 20089, Italy
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Nagoya, Aichi-ken, 4678602, Japan
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Kofu, Yamanashi, 400-8506, Japan
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Niigata, 9518520, Japan
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Amsterdam, North Holland, 1105 AZ, Netherlands
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Rotterdam, South Holland, 3015 GD, Netherlands
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Madrid, 28006, Spain
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Madrid, 28041, Spain
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Pontevedra, 36003, Spain
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoMayo Clinic Jacksonville, Jacksonville, Florida, 32224, United States
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoLas Vegas Dermatology, Las Vegas, Nevada, 89144, United States
1-888-669-6682
FAQOther Questions
- Red Wine and Vitiligo
Recent research has explored whether moderate red wine consumption might influence vitiligo risk, especially through genetic studies and large population data. What the Genetic ...
- Vitiligo and hearing loss: any connection?
Vitiligo is primarily recognized for causing skin discoloration, but it can also impact melanocytes in unexpected areas, such as the inner ear. This raises questions about wheth...
- Isn't it just a cosmetic disorder?
Contrary to popular belief, vitiligo is not merely a cosmetic issue but a complex autoimmune disorder that affects the body’s largest organ—along with other vital systems—and is...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.